logo-loader
RNS
4basebio PLC

4basebio Plc - Director Appointment

A blue text on a black backgroundAI-generated content may be incorrect.

4basebio PLC

("4basebio" or the "Company")

 

Director Appointment

 

CAMBRIDGE, UK – 08 July 2026   –   4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, is pleased to announce the apppointent of Mr. Cornel Chiriac as Non-executive Director of the Company with immediate effect.

 

Mr. Chiriac currently serves as an investment director at M&G Investments’ Crossover Fund, and brings 25 years of experience in investing and portfolio and operational management, with 10 years focused on deep tech and science venture capital.

 

Earlier in his career, Mr. Chiriac was a founding partner of 2050 Capital, a London-based deep tech and science venture capital firm, through which he holds a number of portfolio directorships. Prior to that, he built and scaled two ventures in the USA to multi-million-dollar exits, having begun his career as a strategy and deal consultant with L.E.K. Consulting. He holds an MBA from the University of Chicago Booth School of Business.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Mr. Corneliu (“ Cornel ”) Chiriac (aged 49):

 


 Current Directorships        Previous Directorships held in the past five years

2050 Capital Limited         Elemente LLC

Autonomous Manufacturing Ltd International Kilobar Association Ltd

Bit Bio Limited              The Naked Pharmacy Ltd

Blue Elm Limited

Hadean Supercomputing Ltd

OSCPS Motion Sensing Inc

TriEye Limited



 

Mr. Chiriac holds no Ordinary Shares, and no options or warrants over Ordinary Shares. There is no further information regarding Mr. Chiriac that is required to be disclosed under the AIM Rules.

 

Dr. Amy Walker, CEO of the Company said: “ 'I am delighted to welcome Cornel to the 4basebio Board following his involvement in the Company for the last two years representing M&G. His strategic perspective, thoughtful approach and strong understanding of scaling innovative technology businesses will be a valuable addition as we continue to grow our commercial business and execute our long-term strategy. I look forward to working with him as we build on our momentum and create further value for shareholders .”

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:


 4basebio PLC                                     +44 (0)12 2396 7943

Dr Amy Walker, CEO



 Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880

Jo Turner / Sandy Jamieson / Ed Downes





 Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500

Geoff Nash / Nigel Birks





 RBC Capital Markets (Joint Broker)               +44 (0)20 7653 4000

Kathryn Deegan / Matthew Coakes



 ICR Healthcare (Media and Investor Relations)    +44 (0)203 707 5700

Mary-Jane Elliott / Jessica Hodgson





 

 

 

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.

 

For more information, visit 4basebio.com .

 

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio.   Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.





4372176_0.png




NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

7 min read